Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamlanivimab (LY3819253) Phase 1 in Hospitalized COVID-19
NCT04411628Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bamlanivimab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Events Considered Related to Study Drug. Started May 2020; status: completed.
02
Drugs
bamlanivimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04411628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411628.